Home
Resources
Publications
Two Formulations of Epoprostenol Sodium in the Treatment of Pulmonary Arterial Hypertension: EPITOME-1 (Epoprostenol for Injection in Pulmonary Arterial Hypertension), a Phase IV, Open-Label, Randomized Study

Two Formulations of Epoprostenol Sodium in the Treatment of Pulmonary Arterial Hypertension: EPITOME-1 (Epoprostenol for Injection in Pulmonary Arterial Hypertension), a Phase IV, Open-Label, Randomized Study

Kelly M Chin, David B Badesch, Ivan M Robbins, Victor F Tapson, Harold I Palevsky, Nick H Kim, Steven M Kawut, Adaani Frost, Wade W Benton, Jean-Christophe Lemarie, Frederic Bodin, Lewis J Rubin, Vallerie McLaughlin

Am Heart J. 2014 Feb;167(2):218-225.e1.

PMID: 24439983

Abstract:

Background:
Epoprostenol sodium with arginine-mannitol excipients (epoprostenol AM; Veletri [Actelion Pharmaceuticals Ltd, Allschwil, Switzerland]) and epoprostenol sodium with glycine-mannitol excipients (epoprostenol GM; Flolan [GlaxoSmithKline, Triangle Park, NC]) are intravenous treatments for pulmonary arterial hypertension (PAH). Epoprostenol AM contains different inactive excipients, resulting in greater stability at room temperature compared with epoprostenol GM.
Methods:
In this prospective, multicenter, open-label, randomized, phase IV exploratory study, epoprostenol-naïve patients in need of injectable prostanoid therapy were randomized 2:1 to open-label epoprostenol AM or epoprostenol GM. The study period was 28 days, followed by a 30-day safety follow-up. Study aims were to descriptively compare the safety, tolerability, drug metabolite levels, and treatment effects of epoprostenol AM and epoprostenol GM in PAH. Statistical analysis was descriptive only because of the exploratory nature of the study.
Results:
Thirty patients with PAH (18-70 years, 24 women, 20 idiopathic PAH) were randomized to epoprostenol AM (n = 20) or epoprostenol GM (n = 10). Most frequently reported adverse events included jaw pain, headache, nausea, and flushing. Two deaths occurred during the study period, and 1 death occurred during the 30-day safety follow-up period, all in patients receiving epoprostenol AM. All deaths were classified by the treating physician as unrelated to epoprostenol AM. The median (range) change from baseline to day 28 in 6-minute walk distance was 36 m (-127 to 210 m) and 49 m (-44 to 110 m) for the epoprostenol AM and epoprostenol GM groups, respectively.
Conclusions:
In this randomized clinical study of epoprostenol AM in PAH, use of this novel preparation with greater room temperature stability was well tolerated.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP61849147-A	Epoprostenol sodium		61849-14-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: